The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Metabolism
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1545086
Metabolic Reprogramming of Glucose:The Metabolic Basis for the Occurrence and Development of Hepatocellular Carcinoma
Provisionally accepted- 1 Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
- 2 Zhangzi County Maternal and Child Health Family Planning Service Center, Changzhi City, China
Primary liver cancer is a common malignant tumor of the digestive system, with hepatocellular carcinoma (HCC) being the most prevalent type. It is characterized by high malignancy, insidious onset, and a lack of specific early diagnostic and therapeutic markers, posing a serious threat to human health. The occurrence and development of HCC are closely related to its metabolic processes. Similar to other malignant tumors, metabolic reprogramming occurs extensively in tumor cells, with glucose metabolism reprogramming being particularly prominent. This is characterized by abnormal activation of glycolysis and inhibition of oxidative phosphorylation and gluconeogenesis, among other changes. Glucose metabolism reprogramming provides intermediates and energy for HCC to meet its demands for rapid growth, proliferation, and metastasis. Additionally, various enzymes and signaling molecules involved in glucose metabolism reprogramming play irreplaceable roles. Therefore, regulating key metabolic enzymes and pathways in these processes is considered an important target for the diagnosis and treatment of HCC. This paper reviews the current status and progress of glucose metabolism reprogramming in HCC, aiming to provide new insights for the diagnosis, detection, and comprehensive treatment strategies of HCC involving combined glucose metabolism intervention in clinical settings.Key Word : Hepatocellular Carcinoma (HCC) , Metabolic Reprogramming , Glucose Metabolism
Keywords: hepatocellular carcinoma (HCC), metabolic reprogramming, glucose metabolism, Glycolytic pathway, Pentose phosphate pathway (PPP)
Received: 14 Dec 2024; Accepted: 20 Jan 2025.
Copyright: © 2025 Wang, Li, Guo, Chen, Lv, Guo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kai Wang, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.